| Drug Name | (Actos (PIOGLITAZONE |
|---|---|
| Drug Class |
Anti-diabetic
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
Safety communication
|
| Specialty (Theraputic area) |
Endocrine
|
| Risk |
Risk of bladder cancer Saudi Food and Drug Authority (SFDA) PRESS RELEASE – Safety of Pioglitazone - (Actos®) |
| safety communication |
|
| Dear Healthcare provider letter DHPC |
|